SG11202005112TA - Heterocyclic compounds as prmt5 inhibitors - Google Patents

Heterocyclic compounds as prmt5 inhibitors

Info

Publication number
SG11202005112TA
SG11202005112TA SG11202005112TA SG11202005112TA SG11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA SG 11202005112T A SG11202005112T A SG 11202005112TA
Authority
SG
Singapore
Prior art keywords
heterocyclic compounds
prmt5 inhibitors
prmt5
inhibitors
heterocyclic
Prior art date
Application number
SG11202005112TA
Other languages
English (en)
Inventor
Wen-Lian Wu
Zhiqiang Yang
Francis Lee
John Qiang Tan
Original Assignee
Angex Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angex Pharmaceutical Inc filed Critical Angex Pharmaceutical Inc
Publication of SG11202005112TA publication Critical patent/SG11202005112TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
SG11202005112TA 2017-12-05 2018-11-01 Heterocyclic compounds as prmt5 inhibitors SG11202005112TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594898P 2017-12-05 2017-12-05
PCT/US2018/058721 WO2019112719A1 (fr) 2017-12-05 2018-11-01 Composés hétérocycliques en tant qu'inhibiteurs de prmt5

Publications (1)

Publication Number Publication Date
SG11202005112TA true SG11202005112TA (en) 2020-06-29

Family

ID=66750587

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005112TA SG11202005112TA (en) 2017-12-05 2018-11-01 Heterocyclic compounds as prmt5 inhibitors

Country Status (9)

Country Link
US (1) US20200369667A1 (fr)
EP (1) EP3720495A4 (fr)
JP (1) JP2021505583A (fr)
KR (1) KR20200096265A (fr)
CN (1) CN111741964A (fr)
AU (1) AU2018381004B2 (fr)
CA (1) CA3084253A1 (fr)
SG (1) SG11202005112TA (fr)
WO (1) WO2019112719A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
KR20210145787A (ko) 2019-04-02 2021-12-02 알리고스 테라퓨틱스 인코포레이티드 Prmt5를 표적으로 하는 화합물
JP2022534998A (ja) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｒｍｔ５阻害剤としての複素環式化合物
AU2020372002A1 (en) * 2019-10-21 2022-05-26 Accent Therapeutics, Inc Mettl3 modulators
AU2021319201A1 (en) 2020-07-31 2023-02-16 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2606514C2 (ru) * 2010-12-03 2017-01-10 Эпизайм, Инк. Замещенные пуриновые и 7-деазапуриновые соединения
CN103339139A (zh) * 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
WO2017153186A1 (fr) * 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Analogues de nucléosides substitués destinés à être utilisés en tant qu'inhibiteurs de prmt5
CA2969295A1 (fr) * 2016-06-06 2017-12-06 Pfizer Inc. Derives de carbonucleosides substitues et leur utilisation comme inhibiteur de prmt5
GB201700526D0 (en) * 2017-01-12 2017-03-01 Univ Of Hull Therapeutic use
WO2018152548A1 (fr) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EA201990851A1 (ru) * 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
US11279970B2 (en) * 2017-02-27 2022-03-22 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
WO2018160824A1 (fr) * 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
WO2018160855A1 (fr) * 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
GB201709406D0 (en) * 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC

Also Published As

Publication number Publication date
JP2021505583A (ja) 2021-02-18
CA3084253A1 (fr) 2019-06-13
AU2018381004A1 (en) 2020-06-18
WO2019112719A1 (fr) 2019-06-13
US20200369667A1 (en) 2020-11-26
CN111741964A (zh) 2020-10-02
EP3720495A4 (fr) 2021-06-02
EP3720495A1 (fr) 2020-10-14
AU2018381004B2 (en) 2021-04-29
KR20200096265A (ko) 2020-08-11

Similar Documents

Publication Publication Date Title
ZA202003778B (en) Heterocyclic compounds as prmt5 inhibitors
HK1249905A1 (zh) 作為lsd1抑制劑的雜環化合物
IL276509A (en) Heterocyclic compounds as kinase inhibitors
IL273428A (en) Heterocyclic compounds as PAD inhibitors
ZA202003528B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
HUE059324T2 (hu) Heterociklusos vegyületek, mint PI3K-gamma inhibitorok
IL269188A (en) The heterocyclic compounds useful as dual inhibitors of ATX / CA.
IL267781A (en) Heterocyclic spiro compounds as magl inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
SG11202005112TA (en) Heterocyclic compounds as prmt5 inhibitors
IL282659A (en) Heterocyclic compounds as bet inhibitors
IL266789A (en) Heterocyclic compounds as kinase inhibitors
PT3643718T (pt) Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
EP3660003C0 (fr) Composé hétérocyclique
EP3693360C0 (fr) Composés hétérocycliques
EP3693368C0 (fr) Composé hétérocyclique
ZA201907792B (en) Heterocyclic compound
ZA201907793B (en) Heterocyclic compound